Sentinel Node Biopsy in Patients With Thin Melanoma: A Need to Better Define the Aim
- 20 September 2020
- journal article
- letter
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (27), 3237-3238
- https://doi.org/10.1200/jco.20.01199
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Systemic Therapy for Melanoma: ASCO GuidelineJournal of Clinical Oncology, 2020
- Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive NomogramJournal of Clinical Oncology, 2020
- What Is the Role of Dabrafenib Plus Trametinib Adjuvant Therapy in Stage IIIA Melanoma?Journal of Clinical Oncology, 2019
- Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2019
- Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III MelanomaJournal of Clinical Oncology, 2018
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaThe New England Journal of Medicine, 2018
- Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2018
- Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manualCA: A Cancer Journal for Clinicians, 2017
- Age as a Predictor of Sentinel Node Metastasis among Patients with Localized Melanoma: An Inverse Correlation of Melanoma Mortality and Incidence of Sentinel Node Metastasis Among Young and Old PatientsAnnals of Surgical Oncology, 2014
- Factors Associated with False-Negative Sentinel Lymph Node Biopsy in Melanoma PatientsAnnals of Surgical Oncology, 2009